Therapeutic approaches to diabetic nephropathy--beyond the RAS. (Q38209811)

31 August 2017

Therapeutic approaches to diabetic nephropathy--beyond the RAS. (English)

1 reference

31 August 2017

Alberto Ortiz

2

0 references

author name string

Beatriz Fernandez-Fernandez

series ordinal

1

1 reference

31 August 2017

Carmen Gomez-Guerrero

series ordinal

3

1 reference

31 August 2017

Jesus Egido

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

6 May 2014

1 reference

Nature Reviews Nephrology

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

325-346

1 reference

31 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2014.74

31 August 2017

0 references

cites work

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Kidney disease and increased mortality risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

US Renal Data System 2013 Annual Data Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Uric acid and the state of the intrarenal renin-angiotensin system in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

BASP1 promotes apoptosis in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

DPP-4 inhibitors: what may be the clinical differentiators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: the DEMAND study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Short-term changes after a weight reduction intervention in advanced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Management of dyslipidemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The Nrf2 pathway in the progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The expanding spectrum of biological actions of vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Vitamin D receptor activation and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Pyridorin in type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

D-saccharic acid 1,4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-κB and PKC signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Pirfenidone for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Aldosterone-induced fibrosis in the kidney: questions and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Diabetes and gout: efficacy and safety of febuxostat and allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Targeting chemokines in proteinuria-induced renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Matrix metalloproteinases in kidney homeostasis and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

ADAM-17: the enzyme that does it all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

NF-kappaB in renal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Bindarit: an anti-inflammatory small molecule that modulates the NFκB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

AG490 promotes HIF-1α accumulation by inhibiting its hydroxylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Treatment of streptozotocin-induced diabetes mellitus in rats by transplantation of islet cells from two major histocompatibility complex disparate rats in combination with intra bone marrow injection of allogeneic bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Suppressors of cytokine signaling abrogate diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Fcγ receptor deficiency attenuates diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Tyrosine kinase inhibitor, genistein, reduces renal inflammation and injury in streptozotocin-induced diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Activation of RhoA/ROCK regulates NF-κB signaling pathway in experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Apelin retards the progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Autophagy as a therapeutic target in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

New therapies for diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Reengineering translational science: the time is right

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Implementation of proteomic biomarkers: making it work

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

The GFR and GFR decline cannot be accurately estimated in type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Images in clinical medicine. Paget's disease of the mandible

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Paricalcitol for reduction of albuminuria in diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Oral administration of ethyl acetate-soluble portion of Terminalia chebula conferring protection from streptozotocin-induced diabetic mellitus and its complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

31 March 2020

Ruboxistaurin: LY 333531

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Pentoxifylline for diabetic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Human mesenchymal precursor cells (Stro-1⁺) from spinal cord injury patients improve functional recovery and tissue sparing in an acute spinal cord injury rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Transfused Macrophages Ameliorate Pancreatic and Renal Injury in Murine Diabetes Mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Exogenous activated protein C inhibits the progression of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Adenosine A(2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Proteinuria as a surrogate end point--more data are needed

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.74

Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus

31 March 2020

1 reference

12 December 2020

Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice.

1 reference

12 December 2020

Vitamin D and proteinuria: a critical review of molecular bases and clinical experience.

1 reference

12 December 2020

Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats

1 reference

12 December 2020

The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Endothelin antagonists for diabetic and non-diabetic chronic kidney disease

1 reference

12 December 2020

Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats.

1 reference

12 December 2020

The clinical course of diabetic nephropathy

1 reference

12 December 2020

2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2014.74

1 reference

31 August 2017

1 reference